Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

B.C.’s biosimilars policy a turning point for private plans

B.C.’s biosimilar switching policy has had a profound impact on private drug plans in the province, according to TELUS Health claims data for private drug plans. 

Read more

Biosimilar switching study demonstrates value of patient support, education

A new study on the BC experience with biosimilars found that "Well-supported switching to biosimilars, in the form of solid education efforts about biosimilar equivalence, leads to successful clinical outcomes and, importantly, patient acceptance of these agents."

Read more

Quebec adds momentum to Canadian biosimilar switching

Generics Bulletin report on Quebec becoming the fourth province in Canada to announce a biosimilar switching policy.

Read more